MESO vs. SWTX, DNLI, TWST, ACLX, NVAX, APGE, ADMA, CGON, IOVA, and VCEL
Should you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include SpringWorks Therapeutics (SWTX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Arcellx (ACLX), Novavax (NVAX), Apogee Therapeutics (APGE), ADMA Biologics (ADMA), CG Oncology (CGON), Iovance Biotherapeutics (IOVA), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry.
SpringWorks Therapeutics (NASDAQ:SWTX) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends.
Mesoblast received 313 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 70.51% of users gave Mesoblast an outperform vote while only 68.42% of users gave SpringWorks Therapeutics an outperform vote.
SpringWorks Therapeutics currently has a consensus target price of $68.83, indicating a potential upside of 71.14%. Mesoblast has a consensus target price of $13.67, indicating a potential upside of 91.41%. Given SpringWorks Therapeutics' higher possible upside, analysts clearly believe Mesoblast is more favorable than SpringWorks Therapeutics.
Mesoblast has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.
1.4% of Mesoblast shares are owned by institutional investors. 7.6% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
SpringWorks Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.46, indicating that its stock price is 246% more volatile than the S&P 500.
SpringWorks Therapeutics' return on equity of 0.00% beat Mesoblast's return on equity.
In the previous week, Mesoblast had 3 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 8 mentions for Mesoblast and 5 mentions for SpringWorks Therapeutics. Mesoblast's average media sentiment score of 1.33 beat SpringWorks Therapeutics' score of 0.17 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
Summary
Mesoblast beats SpringWorks Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Mesoblast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mesoblast Competitors List
Related Companies and Tools
